Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$2.93
-8.7%
$2.95
$0.40
$5.48
$68.98M0.27465,514 shs130,607 shs
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$1.23
-3.1%
$1.46
$1.17
$4.84
$12.40M0.47518,102 shs92,508 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$1.27
+2.4%
$0.87
$0.61
$5.64
$71.88M1.22193,643 shs634,228 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$0.99
+3.5%
$0.86
$0.69
$3.95
$47.60M1.63844,819 shs533,001 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.00%-2.73%+6.64%+179.13%+348.89%
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.00%+1.60%-16.45%-31.35%-50.39%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
0.00%+42.53%+33.33%+39.92%-76.91%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
0.00%-4.00%+13.45%-11.11%-72.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.5097 of 5 stars
0.03.00.00.02.80.80.0
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.3922 of 5 stars
0.03.00.00.00.62.50.0
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.7804 of 5 stars
3.53.00.00.00.93.30.6
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3.4949 of 5 stars
3.45.00.00.02.41.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.00
N/AN/AN/A
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.00
N/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.00
Buy$4.00214.96% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.83
Moderate Buy$7.00604.44% Upside

Current Analyst Ratings Breakdown

Latest BFRG, PRLD, ABVC, and STTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$4.00 ➝ $3.00
8/14/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$4.00 ➝ $2.00
8/14/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$391.24K176.31N/AN/A$0.06 per share48.83
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$33.26K372.84N/AN/A$0.57 per share2.16
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M10.27N/AN/A$2.39 per share0.53
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$5.72M8.32N/AN/A$1.67 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$4.90M-$0.17N/AN/A-963.46%-46.76%-23.02%11/12/2025 (Estimated)
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-$6.99M-$0.76N/AN/AN/A-195.35%-162.37%N/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$127.17M-$1.64N/AN/AN/AN/A-106.50%-79.07%11/5/2025 (Estimated)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)

Latest BFRG, PRLD, ABVC, and STTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.45-$0.41+$0.04-$0.41N/AN/A
8/14/2025Q2 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.25-$0.24+$0.01-$0.24N/AN/A
8/13/2025Q2 2025
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A-$0.13N/A-$0.13N/AN/A
8/13/2025Q2 2025
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/A-$0.15N/A-$0.15N/A$0.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/AN/A
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A
0.42
0.42
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/A
3.97
3.97
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
3.68
3.68
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
10.25
10.25

Institutional Ownership

CompanyInstitutional Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
11.38%
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.96%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%

Insider Ownership

CompanyInsider Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
17.10%
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
24.72%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
3023.54 million19.52 millionNot Optionable
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
410.08 million7.59 millionNot Optionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.60 million20.43 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.16 millionOptionable

Recent News About These Companies

Shattuck Labs Reports Q2 2025 Financial Results
Leerink Partnrs Estimates Shattuck Labs Q1 Earnings
Shattuck Labs expects $103 million from private placing
Shattuck Labs, Inc. (STTK) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC BioPharma stock logo

ABVC BioPharma NASDAQ:ABVC

$2.93 -0.28 (-8.72%)
Closing price 04:00 PM Eastern
Extended Trading
$3.00 +0.07 (+2.56%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRG

$1.23 -0.04 (-3.15%)
Closing price 04:00 PM Eastern
Extended Trading
$1.23 0.00 (0.00%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$1.27 +0.03 (+2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 -0.07 (-5.43%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$0.99 +0.03 (+3.51%)
Closing price 04:00 PM Eastern
Extended Trading
$0.99 +0.00 (+0.03%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.